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Summary 
A number of agents with differing selectivity profiles for the non-a2 • 
adrenoceptor binding site (NAIBS), imidazoline preferring recaptor 
(IPR) and a2-adrenoceptor were employed in a series of behavioural 
and neurochemical experiments to determine a functional role for the 
former two sites. 
The highly selective NAIBS ligand RX801 077 produced an increase 
in rat brain extracellular noradrenaline (NA) levels, as determined by 
the technique of in vivo microdialysis, which may underlie its ability 
to produce a discriminable cue in the same species. This increase in 
NA may be due to a suggested link between the NAIBS and the 
monoamine oxidase inhibitor (MAO!) activity of RX801 077. For 
instance, the RX801 077 cue was substituted for by the MAO I drugs 
pargyline and moclobemide, which themselves down regulate NAIBS 
when administered chronically. RX811 059 substituted for the 
RX801 077 cue which may be due its ability to stimulate NA release 
via its activity as a highly selective a2-adrenoceptor antagonist. An 
effect upon NA output may also explain the ability of RX801 077 to 
'mimic' the anti-immobility effect of the antidepressant drug 
desmethylimipramine (DMJ) in the forced swimming test. Further 
studies are therefore required to examine a possible role for the 
NAIBS in the treatment of depression. 
Discriminable cues were also produced by RX811 059 and the a2-
adrenoceptor agonist clonidine, probably as a consequence of their 
respective ability to stimulate and inhibit NA output via their 
opposing activity at a2-adrenoceptors. The IPR has been suggested to 
play a role in mediating the hypotensive effect of clonidine, although a 
precise role was unable to be established for this site in the present 
studies due to the unavailability of highly selective IPA agents. 
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